Do analysts recommend AIXC or VRCA?

Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 135.77%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer AIXC or VRCA?

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.63 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PEPG or AIXC?

PepGen currently has a consensus price target of $11.60, suggesting a potential upside of 683.78%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, PEPG or AIXC?

PepGen is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is PEPG or AIXC more profitable?

PepGen's return on equity of -59.89% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Qualigen Therapeutics N/A -771.52% -79.52%

Does the media favor PEPG or AIXC?

In the previous week, PepGen had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat PepGen's score of 0.51 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIXC or CRDF?

Cardiff Oncology has a consensus price target of $8.75, indicating a potential upside of 464.52%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardiff Oncology 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to AIXC or CRDF?

In the previous week, Cardiff Oncology had 5 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Cardiff Oncology's score of 0.06 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend AIXC or BMEA?

Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 522.71%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better earnings and valuation, AIXC or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is AIXC or BMEA more profitable?

Biomea Fusion's return on equity of -265.37% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Biomea Fusion N/A -265.37% -103.96%

Does the media prefer AIXC or BMEA?

In the previous week, Biomea Fusion had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIXC or FTLF?

FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 116.30%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer AIXC or FTLF?

In the previous week, FitLife Brands had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for FitLife Brands and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat FitLife Brands' score of 0.39 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FitLife Brands 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Qualigen Therapeutics (AIXC) Competitors

$1.29 +0.03 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 -0.01 (-0.39%)

As of 06:22 PM Eastern

Compare

AIXC vs. VRCA, PEPG, CRDF, BMEA, and FTLF

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include Verrica Pharmaceuticals (VRCA), PepGen (PEPG), Cardiff Oncology (CRDF), Biomea Fusion (BMEA), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to Verrica Pharmaceuticals?

Qualigen Therapeutics (NASDAQ:AIXC) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Qualigen Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Qualigen Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Qualigen Therapeutics' return on equity of -771.52% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Qualigen Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Verrica Pharmaceuticals	$35.58M	2.97	-$17.89M	-$1.03	N/A

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.63 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 135.77%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Verrica Pharmaceuticals beats Qualigen Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Qualigen Therapeutics compare to PepGen?

PepGen (NASDAQ:PEPG) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, PepGen had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat PepGen's score of 0.51 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PepGen has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

58.0% of PepGen shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PepGen is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

PepGen currently has a consensus price target of $11.60, suggesting a potential upside of 683.78%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PepGen's return on equity of -59.89% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Summary

PepGen beats Qualigen Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Cardiff Oncology?

Qualigen Therapeutics (NASDAQ:AIXC) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Qualigen Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Qualigen Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, Cardiff Oncology had 5 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Cardiff Oncology's score of 0.06 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cardiff Oncology has a consensus price target of $8.75, indicating a potential upside of 464.52%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Qualigen Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Cardiff Oncology	$590K	179.62	-$45.85M	-$0.67	N/A

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cardiff Oncology beats Qualigen Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Biomea Fusion?

Qualigen Therapeutics (NASDAQ:AIXC) and Biomea Fusion (NASDAQ:BMEA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 522.71%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Qualigen Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Biomea Fusion's return on equity of -265.37% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Biomea Fusion	N/A	-265.37%	-103.96%

In the previous week, Biomea Fusion had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Biomea Fusion is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

Biomea Fusion beats Qualigen Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to FitLife Brands?

Qualigen Therapeutics (NASDAQ:AIXC) and FitLife Brands (NASDAQ:FTLF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Qualigen Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

FitLife Brands has a consensus target price of $21.50, indicating a potential upside of 116.30%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

FitLife Brands has a net margin of 6.64% compared to Qualigen Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
FitLife Brands	6.64%	18.31%	8.21%

In the previous week, FitLife Brands had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for FitLife Brands and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.93 beat FitLife Brands' score of 0.39 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FitLife Brands	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 61.4% of FitLife Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

FitLife Brands has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
FitLife Brands	$81.46M	1.15	$6.33M	$0.60	16.57

Summary

FitLife Brands beats Qualigen Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIXC vs. The Competition

Export

Metric	Qualigen Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$26.11M	$993.39M	$4.35B	$12.46B
Dividend Yield	N/A	4.84%	7.42%	5.22%
P/E Ratio	-0.20	1.49	21.82	24.36
Price / Sales	N/A	125.49	176.08	117.06
Price / Cash	N/A	20.06	58.60	57.13
Price / Book	-1.72	8.12	30.95	6.73
Net Income	-$16.97M	-$3.91M	$109.80M	$337.03M
7 Day Performance	4.88%	-1.73%	-0.42%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	N/A	111.96%	15.64%	33.98%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIXC Qualigen Therapeutics	0.5126 of 5 stars	$1.29 +2.4%	N/A	N/A	$26.11M	N/A	N/A	50
VRCA Verrica Pharmaceuticals	2.8232 of 5 stars	$5.86 +1.2%	$14.50 +147.4%	+10.5%	$101.19M	$35.58M	N/A	40
PEPG PepGen	3.0193 of 5 stars	$1.42 -1.8%	$11.60 +714.6%	-7.2%	$98.57M	N/A	N/A	30	Analyst Downgrade
CRDF Cardiff Oncology	2.2089 of 5 stars	$1.41 -7.0%	$8.75 +522.8%	-60.1%	$96.06M	$590K	N/A	20	News Coverage Analyst Downgrade High Trading Volume
BMEA Biomea Fusion	2.0394 of 5 stars	$1.30 -5.4%	$8.50 +555.9%	-47.8%	$94.35M	N/A	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIXC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. VRCA, PEPG, CRDF, BMEA, and FTLF

How does Qualigen Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Qualigen Therapeutics compare to PepGen?

Summary

How does Qualigen Therapeutics compare to Cardiff Oncology?

Summary

How does Qualigen Therapeutics compare to Biomea Fusion?

Summary

How does Qualigen Therapeutics compare to FitLife Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. VRCA, PEPG, CRDF, BMEA, and FTLF

How does Qualigen Therapeutics compare to Verrica Pharmaceuticals?

Which has more volatility and risk, AIXC or VRCA?

Do institutionals and insiders have more ownership in AIXC or VRCA?

Is AIXC or VRCA more profitable?

Which has higher earnings and valuation, AIXC or VRCA?

Does the media prefer AIXC or VRCA?

Do analysts recommend AIXC or VRCA?

Summary

How does Qualigen Therapeutics compare to PepGen?

Does the media favor PEPG or AIXC?

Which has more volatility and risk, PEPG or AIXC?

Do insiders & institutionals hold more shares of PEPG or AIXC?

Which has better valuation and earnings, PEPG or AIXC?

Do analysts rate PEPG or AIXC?

Is PEPG or AIXC more profitable?

Summary

How does Qualigen Therapeutics compare to Cardiff Oncology?

Is AIXC or CRDF more profitable?

Which has more volatility and risk, AIXC or CRDF?

Does the media refer more to AIXC or CRDF?

Do analysts recommend AIXC or CRDF?

Which has stronger valuation & earnings, AIXC or CRDF?

Do insiders and institutionals have more ownership in AIXC or CRDF?

Summary

How does Qualigen Therapeutics compare to Biomea Fusion?

Do analysts recommend AIXC or BMEA?

Which has more volatility & risk, AIXC or BMEA?

Is AIXC or BMEA more profitable?

Does the media prefer AIXC or BMEA?

Do insiders & institutionals have more ownership in AIXC or BMEA?

Which has better earnings and valuation, AIXC or BMEA?

Summary

How does Qualigen Therapeutics compare to FitLife Brands?

Which has more risk & volatility, AIXC or FTLF?

Do analysts recommend AIXC or FTLF?

Is AIXC or FTLF more profitable?

Does the media prefer AIXC or FTLF?

Do insiders and institutionals have more ownership in AIXC or FTLF?

Which has better valuation & earnings, AIXC or FTLF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools